ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

j-c healthcare ltd. - אחות - חבישה וניטרול ריחות של פצעים מזוהמים

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 20 mg - afatinib

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 30 mg - afatinib

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 40 mg - afatinib

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 50 mg - afatinib

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

ישראל - עברית - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 250 iu/vial - coagulation factor viii